CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

Core Viewpoint - CytomX Therapeutics, Inc. will report its full year 2025 financial results on March 16, 2026, before U.S. markets open, followed by a conference call and webcast [1] Company Overview - CytomX is a clinical-stage biopharmaceutical company focused on oncology, developing conditionally activated, masked PROBODY® therapeutics aimed at localized tumor treatment [3] - The company’s pipeline includes therapeutic candidates such as varsetatug masetecan (Varseta-M; CX-2051) and CX-801, targeting metastatic colorectal cancer and metastatic melanoma respectively [3] - Varseta-M is a masked ADC with a topoisomerase-1 inhibitor payload, designed to target the epithelial cell adhesion molecule (EpCAM), which is highly expressed in tumors but previously undruggable due to normal tissue expression [3] - CX-801 is a masked interferon alpha-2b PROBODY® cytokine with potential applications in both immuno-oncology sensitive and insensitive tumors [3] - CytomX has established collaborations with major oncology leaders including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3]